Posts in the “Treatment Options Treatment Options” category:

Advancing the development of new “targeted drug therapies” by enhancing the science of biomarkers

Posted by Samantha Powell on October 3rd, 2014 |

A key area of new drug development lies in the field of targeted therapies, sometimes called “personalized medicines,” which are drugs tailored to the genetic makeup of individual patients. These drugs are called targeted therapy because health care professionals can use clinical test results from a patient to select a specific drug that has a […]

Bristol Myers Squibb Getting Close To Lung Cancer Approval For Nivolumab

Posted by Samantha Powell on October 2nd, 2014 |

Bristol-Myers Squibb recently announced key developments regarding its immuno-oncology drug nivolumab. The FDA in the U.S. has granted breakthrough status to the drug for advanced melanoma and has agreed to review the license application on priority basis. The review is likely to be completed by the end of March 2015. Additionally, the EMA (European Medicines […]

AstraZeneca Whale Racing With Minnow to Develop Lung Cancer Drug

Posted by Samantha Powell on October 1st, 2014 |

The race to develop a new class of lung-cancer medicines is pitting one of the world’s biggest drugmakers against a five-year-old startup. AstraZeneca Plc (AZN), the U.K.’s second-largest pharmaceutical company, and Clovis Oncology Inc. (CLVS) of Boulder, Colorado, both intend to seek approval from regulators next year. Both drugs, which target a form of the […]

Bristol-Myers’ oncology star lines up for lung cancer approval, leading the PD-1 pack

Posted by Samantha Powell on September 29th, 2014 |

Among the scrum of drugmakers racing forward with a new class of cancer treatments, Bristol-Myers Squibb ($BMY) was the first to win a global regulatory nod and is now first in line for approval in lung cancer, a particularly lucrative indication for the group of promising oncology drugs. The company has completed a European application […]

CytRx Receives Multiple FDA Orphan Drug Designations for Aldoxorubicin for the Treatment of Glioblastoma, Small Cell Lung Cancer and Ovarian Cancer

Posted by Samantha Powell on September 29th, 2014 |

CytRx Corporation CYTR, -0.36% a biopharmaceutical research and development company specializing in oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted multiple Orphan Drug Designations for the Company’s lead drug candidate, aldoxorubicin, in three indications: glioblastoma multiforme (GBM), small cell lung cancer and ovarian cancer. Aldoxorubicin is CytRx’s modified version of […]

Conventional Surgery May Trump Radiosurgery for Some Early Lung Cancers

Posted by Samantha Powell on September 25th, 2014 |

Despite having a higher rate of early complications, patients with non-small cell lung cancer (NSCLC) did better in the long run with conventional surgery than with radiotherapy to remove their cancer, a finding that supports the current practice of treating healthier patients with surgery instead of radiosurgery. In this study from Yale University using Medicare […]

Stanford licenses promising cancer drug to local biotech startup

Posted by Samantha Powell on September 25th, 2014 |

Most cancer patients don’t die because of a single tumor, but rather multiple tumors that spread throughout the body. A new therapy, developed by Stanford University researchers and licensed by a local biotech startup, appears to disrupt the deadly process known as metastasis, which causes cancer cells to break away from the original tumor sites […]

Curcumin spice linked to slowing of lung lining cancer

Posted by Samantha Powell on September 22nd, 2014 |

A new study has revealed that Asian spice Curcumin show promise in slowing the progression of mesothelioma, a cancer of the lung’s lining often linked to asbestos. According to the study by scientists from Case Western Reserve University and the Georg-Speyer-Haus in Frankfurt, Germany, the spice which is a derivative of the spice turmeric and […]

Dye offers hope for removal of all traces of tumors

Posted by Samantha Powell on September 21st, 2014 |

A third of patients who undergo surgery to remove cancerous tumors end up with microscopic pieces left behind. These overlooked remnants can lead to the recurrence of cancer after what was thought to be a successful surgery. Two surgeons at the University of Pennsylvania have joined forces to try to solve this problem. Their solution: […]

Chest radiation may be useful for combatting advanced lung cancers

Posted by Samantha Powell on September 18th, 2014 |

Adding chest radiation to chemotherapy allows some people with small-cell lung cancer to live longer and cuts recurrence rates by nearly 50 percent, European researchers report. The research was published online Sept. 14 in The Lancet to coincide with presentation at the annual meeting of the American Society for Radiation Oncology, held from Sept. 14 […]